Consumer Reports takes aim at medical device industry; County takes aim at Pfizer tax breaks;

> The influential Consumer Reports, which reviews consumer products, is taking aim at the FDA's fast-track process for the approval of medical devices, saying some of them could be a "ticking time bomb." Story

> Lee County, NC, commissioners are considering revoking hundreds of thousands of dollars worth of tax incentives for Pfizer ($PFE). The pharmaceutical company is scaling back at its Sanford, NC, plant, so the commissioners may demand a refund of rebates the drugmaker has already received. News

> Ranbaxy Laboratories ($RANBXY.NS), has started operations at a new facility in Morocco, its third in Africa. Story

> Drugmaker Mylan ($MYL) expects to complete by next year a 280,000-square-foot, LEED-certified headquarters facility near its current location in Washington County, PA. Mylan release

> Japan's Asahi Kasei will buy Zoll Medical ($ZOLL), the Chelmsford, MA, maker of software--as well as resuscitation and critical care devices--for $2.21 billion. News

> DSM Pharmaceutical Products, which has been manufacturing the cancer therapy talactoferrin for Agennix for use in clinical trials, has an agreement to produce the med at commercial levels upon its potential approval. Item

> U.K.-based SCM Pharma, a contract development and manufacturing organization that specializes in sterile manufacturing, has invested £500,000 in new vial filling equipment to meet the needs of a new order. Release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.